BioMOF (Biocompatible Metal-Organic Framework) of zinc as a system for the release of metal-drugs with anticancer activity

• Grant number: 17/13961-0
• Support Opportunities: Scholarships in Brazil - Scientific Initiation
• Start date: September 01, 2017
• End date: December 08, 2020
• Field of knowledge: Physical Sciences and Mathematics - Chemistry - Inorganic Chemistry
• Principal Investigator: Regina Celia Galvao Frem
• Grantee: Renan Augusto Marson Armando
• Host Institution: Instituto de Química (IQ). Universidade Estadual Paulista (UNESP). Campus de Araraquara. Araraquara , SP, Brazil
• Associated scholarship(s): 19/26746-5 - MOF@MOF core-shell superstructures as bimodal drug-delivery systems, BE.EP.IC

Abstract

Drug delivery systems are among the segments with the greatest potential for application in the pharmaceutical industry, due to the possibility of optimizing the therapeutic effects and reducing the adverse effects inherent to the drug. Currently, the most widely used systems for drug delivery are liposomes, nanoparticles, nanoemulsions or micelles, the main limitation of which is associated with the low drug incorporation capacity, generally less than 5% by weight of the drug transported relative to the carrier materials. In order to overcome this pharmacological barrier, new systems have been studied and developed, among them a new porous material known as MOF (Metal-Organic Framework). Metal-organic framework belong to a new class of materials of the group of coordination polymers and are highly designed crystalline solids with covalent capacity between metal ions or clusters and polydentate organic binders. There are no doubts and topical about biological applications of this class of materials, such as BioMOFs, biocompatible MOFs, which are constructed from biologically compatible building blocks such as bioelements (Zn, Fe, Cu) and binders such as amino acids, peptides, Nitrogenic bases, etc. In recent years, the interest in obtaining new metal-based drugs for the treatment of cancer has considerably increased. A discovery of the biological activity of cisplatin and its subsequent as an untreated cancer drug has boosted the study of numerous analogous complexes, which generally exhibited similarities in antitumor activity. (II), coordination compounds containing Pd (II) are being investigated for the same purpose. Thus, this work aims to synthesize a BioMoF-1, obtained from the interaction between Zn (II) ions, adenine and the 4,4'-biphenyldicarboxylic linker, and to investigate the potential use of this material as PdCl (PPh3) L)] (PPh3 = triphenylphosphine, L = N-ethyl-1-iminothiolate-3,5-dimethylpyrazole or frambionathiosemicarbazone), which have proven anticancer properties (IC 50 <1 ¼mol L -1 for a breast cancer lineage MCF-7). (AU)

Scientific publications

(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)

MARSON ARMANDO, RENAN AUGUSTO; ABUCAFY, MARINA PAIVA; GRAMINHA, ANGELICA ELLEN; DA SILVA, ROBERTO SANTANA; GALVAO FREM, REGINA CELIA. Ru-90@bio-MOF-1: A ruthenium(II) metallodrug occluded in porous Zn-based MOF as a strategy to develop anticancer agents. Journal of Solid State Chemistry, v. 297, MAY 2021. (19/19453-1, 17/13961-0)